Xintela’s chairman about the company’s journey
Gregory Batcheller has been the chairman of biopharma Xintela since 2011. During this time he has seen the company reach several milestones and now has two ongoing clinical phase I/IIa studies with XSTEM. Batcheller visited BioStock’s studio to tell us more about the company’s journey and business development.
See the interview with Xintela’s chairman Gregory Batcheller here.
Learn more about Xintela here.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
